NasdaqGS - Delayed Quote • USD
DBV Technologies S.A. (DBVT)
At close: April 26 at 4:00 PM EDT
Earnings Estimate
CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 3 |
Avg. Estimate | -0.15 | -0.21 | -0.68 | -0.82 |
Low Estimate | -0.17 | -0.23 | -0.77 | -1.15 |
High Estimate | -0.12 | -0.18 | -0.49 | -0.42 |
Year Ago EPS | -0.49 | -0.11 | -1.3 | -0.68 |
Revenue Estimate
CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
No. of Analysts | 3 | 3 | 3 | 3 |
Avg. Estimate | 6.09M | 2.28M | 12.99M | 9.44M |
Low Estimate | 420k | 1.59M | 7.32M | 6.34M |
High Estimate | 8.97M | 3.23M | 15.82M | 13.91M |
Year Ago Sales | -- | 1.63M | 5.08M | 12.99M |
Sales Growth (year/est) | -- | 39.90% | 155.70% | -27.30% |
Earnings History
CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
---|---|---|---|---|
EPS Est. | -0.18 | -0.2 | -0.2 | -0.24 |
EPS Actual | -0.49 | -0.11 | -0.13 | -0.09 |
Difference | -0.31 | 0.09 | 0.07 | 0.15 |
Surprise % | -172.20% | 45.00% | 35.00% | 62.50% |
EPS Trend
CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
Current Estimate | -0.15 | -0.21 | -0.68 | -0.82 |
7 Days Ago | -0.15 | -0.21 | -0.67 | -0.81 |
30 Days Ago | -0.15 | -0.21 | -0.67 | -0.81 |
60 Days Ago | -0.26 | -0.19 | -0.83 | -0.89 |
90 Days Ago | -0.23 | -0.18 | -0.76 | -0.82 |
EPS Revisions
CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
CURRENCY IN USD | DBVT | Industry | Sector | S&P 500 |
---|---|---|---|---|
Current Qtr. | 69.40% | -- | -- | 5.40% |
Next Qtr. | -90.90% | -- | -- | 10.90% |
Current Year | 47.70% | -- | -- | 4.50% |
Next Year | -20.60% | -- | -- | 13.10% |
Next 5 Years (per annum) | 21.22% | -- | -- | 10.94% |
Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
Reiterates | HC Wainwright & Co.: Buy to Buy | 2/21/2024 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 11/13/2023 |
Maintains | Goldman Sachs: Sell to Sell | 11/2/2023 |
Reiterates | JMP Securities: Market Outperform to Market Outperform | 8/1/2023 |
Reiterates | HC Wainwright & Co.: Buy to Buy | 8/1/2023 |
Reiterates | JMP Securities: Market Outperform to Market Outperform | 5/11/2023 |
Related Tickers
CMMB Chemomab Therapeutics Ltd.
0.6399
-2.90%
XCUR Exicure, Inc.
0.5001
-1.56%
SNTI Senti Biosciences, Inc.
0.2900
+4.05%
GNFT Genfit S.A.
3.4900
+2.35%
ARTL Artelo Biosciences, Inc.
1.3399
+0.74%
TIL Instil Bio, Inc.
10.60
+2.02%
LIPO Lipella Pharmaceuticals Inc.
0.7110
+0.98%
ONCT Oncternal Therapeutics, Inc.
8.29
+0.97%
FHTX Foghorn Therapeutics Inc.
5.49
+4.97%
FBRX Forte Biosciences, Inc.
0.7163
-0.07%